metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone
	IMpower-110 (TC1/2/3 or IC1/2/3), 2020 J Thorac Oncol . 2021 Jul 12;S1556-0864(21)02286-3. NCT02409342	RCT	mNSCLC - L1 - PDL1 positive	atezolizumab	platinium chemotherapy	PD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 1/2/3)	277 / 277	some concern	inconclusive	inconclusive 17 % decrease in deaths (OS) (PE) suggested 28 % decrease in PFS (extension) suggested 23 % decrease in progression or deaths (PFS)
	IMpower-110 (TC3 or IC3), 2020 NCT02409342	RCT	mNSCLC - L1 - PDL1 positive	atezolizumab	platinum chemotherapy	PD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 3)	107 / 98	some concern	conclusif	demonstrated 41 % decrease in deaths (OS) (PE) suggested 41 % decrease in PFS (extension) suggested 37 % decrease in progression or deaths (PFS)
	IMpower-110 (TC2/3 or IC2/3), 2020 NCT02409342	RCT	mNSCLC - L1 - PDL1 positive	atezolizumab	platinium chemotherapy	PD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC2/3)	166 / 162	some concern	suggested	suggested 28 % decrease in deaths (OS) (PE) suggested 36 % decrease in PFS (extension) suggested 33 % decrease in progression or deaths (PFS)
non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population
versus atezolizumab plus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel
	IMpower-130 (all population), 2019 Lancet Oncol. 2019; 20:924-937 NCT02367781	RCT	non squamous - mNSCLC - L1 - all population	atezolizumab plus carboplatin plus nab-paclitaxel (ACnp)	carboplatine plus nab-paclitaxel (CnP)	first-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer and no ALK or EGFR mutations who have not previously received chemotherapy	483 / 240	some concern	conclusif	demonstrated 20 % decrease in deaths (OS) (PE) demonstrated 35 % decrease in progression or deaths (PFS) (PE)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
	IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 N. Engl. J. Med. 2018; 378:2288-2301 Lancet Respir Med 2019; 7:387-401 Cancers Br J Cancer. 2022 Jan;126(1):42-47 NCT02366143	RCT	non squamous - mNSCLC - L1 - all population	atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)	bevacizumab plus carboplatin plus paclitaxel (BCP)	patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.	400 / 400	some concern	inconclusive	suggested 24 % decrease in deaths (OS) suggested 39 % decrease in progression or deaths (PFS)
	atezolizumab plus carboplatin plus paclitaxel
	IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 N. Engl. J. Med. 2018; 378:2288-2301 Lancet Respir Med 2019; 7:387-401 NCT02366143	RCT	non squamous - mNSCLC - L1 - all population	atezolizumab plus carboplatin plus paclitaxel (ACP)	bevacizumab and caroplatin plus paclitaxel (BCP)	patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.	402 / 400	some concern	inconclusive	no statistically significant result
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
	IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 N. Engl. J. Med. 2018; 378:2288-2301 Lancet Respir Med 2019; 7:387-401 NCT02366143	RCT	non squamous - mNSCLC - L1 - Wild Type (WT)	atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)	bevacizumab plus carboplatin plus paclitaxel (BCP)	patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.	155 / 129	some concern	conclusif	demonstrated 49 % decrease in progression or deaths (PFS) (PE)
	IMpower-150 (ABCP vs BPC WT), 2018 N. Engl. J. Med. 2018; 378:2288-2301 Lancet Respir Med 2019; 7:387-401 J Thorac Oncol. 2021 Jul 24 J Thorac Oncol 2022; 17:309-323-. NCT02366143	RCT	non squamous - mNSCLC - L1 - Wild Type (WT)	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP)	bevacizumab and caroplatin plus paclitaxel (BCP)	patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.	356 / 336	some concern	conclusif	demonstrated 22 % decrease in deaths (OS) (PE) demonstrated 38 % decrease in progression or deaths (PFS) (PE)
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel
	IMpower-130 (WT), 2019 Lancet Oncol. 2019; 20:924-937 NCT02367781	RCT	non squamous - mNSCLC - L1 - Wild Type (WT)	atezolizumab (ACnP) plus carboplatine plus nab-paclitaxel	carboplatine plus nab-paclitaxel	first-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer who have not previously received chemotherapy. (EGFRwt and ALKwt)	451 / 228	some concern	conclusif	demonstrated 21 % decrease in deaths (OS) (PE) demonstrated 36 % decrease in progression or deaths (PFS) (PE) statistically significant 1.4-fold increase in DOR
versus pemetrexed plus platin
	atezolizumab plus pemetrexed and platin
	IMpower-132 (WT) unpublished NCT02657434	RCT	non squamous - mNSCLC - L1 - Wild Type (WT)	Atezolizumab (induction and maintenance) plus pemetrexed plus platine	pemetrexed plus platine	Chemotherapy-naive patients with Stage IV non-squamous NSCLC without EGFR or ALK genetic alteration	292 / 286	NA	conclusif	inconclusive 19 % decrease in deaths (OS) (PE) demonstrated 40 % decrease in progression or deaths (PFS) (PE)
squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel
	IMpower-131 (ACnP), 2020 J Thorac Oncol 2020 Aug;15(8):1351-1360. NCT02367794	RCT	squamous - mNSCLC - L1 - all population	atezolizumab plus carboplatine plus nab-paclitaxel(ACnP)	carboplatine plus nab-paclitaxel (CnP)	chemotherapy-naive participants with Stage IV squamous NSCLC	343 / 340	some concern	conclusif	inconclusive 12 % decrease in deaths (OS) (PE) demonstrated 29 % decrease in progression or deaths (PFS) (PE) statistically significant 1.1-fold increase in DOR
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	atezolizumab alone
	OAK (all population), 2016 Lancet 2017;389:255-265 Clin Lung Cancer 2018; 19:e405-e415 Clin Lung Cancer 2018; 19:441-449.e4 Eur. J. Cancer 2019; 107:124-132 J Thorac Oncol 2018; 13:1156-1170 J Med Econ 2019; 22:625-637 Lung Cancer 2019 Feb;128:105-112. NCT02008227	RCT	mNSCLC - L2 - all population	atelozumab	docetaxel	patients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy	613 / 612	some concern	conclusif	demonstrated 20 % decrease in deaths (OS) (PE)
	POPLAR, 2016 Lancet 2016;387:1837-46 J Immunother Cancer 2019; 7:249 NCT01903993	RCT	mNSCLC - L2 - all population	atezolizumab	docetaxel	patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy	144 / 143	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE)
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus docetaxel
	atezolizumab alone
	OAK (PDL1 TC 1/2/3), 2016 Lancet 2017;389:255-265 Clin Lung Cancer 2018; 19:e405-e415 Clin Lung Cancer 2018; 19:441-449.e4 Eur. J. Cancer 2019; 107:124-132 J Thorac Oncol 2018; 13:1156-1170 J Med Econ 2019; 22:625-637 Lung Cancer 2019 Feb;128:105-112. NCT02008227	RCT	mNSCLC - L2 - PDL1 positive	atelozumab	docetaxel	patients with locally advanced or metastatic (IIIB and IV) non-small cell lung cancer (NSCLC) who have failed platinum therapy, only patients with PDL1 TC 1/2/3	347 / 337	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) statistically significant 8.6-fold increase in DOR

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive